Form 8-K - Current report:
SEC Accession No. 0001213900-24-004855
Filing Date
2024-01-19
Accepted
2024-01-19 16:05:40
Documents
14
Period of Report
2024-01-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea191886-8k_onconetix.htm   iXBRL 8-K 28899
2 SEPARATION AGREEMENT, DATED JANUARY 17, 2024, BETWEEN THE COMPANY AND ERIN HENDE ea191886ex10-1_onconetix.htm EX-10.1 179362
3 CONSULTING AGREEMENT, DATED JANUARY 17, 2024, BETWEEN THE COMPANY AND THE AETOS ea191886ex10-2_onconetix.htm EX-10.2 37631
  Complete submission text file 0001213900-24-004855.txt   482419

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE onco-20240117.xsd EX-101.SCH 3042
5 XBRL LABEL FILE onco-20240117_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE onco-20240117_pre.xml EX-101.PRE 22377
8 EXTRACTED XBRL INSTANCE DOCUMENT ea191886-8k_onconetix_htm.xml XML 3423
Mailing Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202
Business Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202 513-620-4101
Onconetix, Inc. (Filer) CIK: 0001782107 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41294 | Film No.: 24545606
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)